{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:27:27Z","timestamp":1778228847763,"version":"3.51.4"},"reference-count":87,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R\/R B-ALL: tisagenlecleucel in patients aged &lt;26 years and brexucabtagene autoleucel in those aged \u226518 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R\/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7065","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:47:04Z","timestamp":1729082824000},"source":"Crossref","is-referenced-by-count":11,"title":["The Role of CAR T-Cell Therapy in Relapsed\/Refractory Adult B-ALL"],"prefix":"10.6004","volume":"22","author":[{"given":"Tamer","family":"Othman","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Haematologica","first-page":"589","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol A","year":"2010","unstructured":"Oriol A, Vives S, Hern\u00e1ndez-Rivas JM,  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589\u2013596."},{"key":"B2","series-title":"Blood","first-page":"4017","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude SL","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017\u20134023."},{"key":"B3","series-title":"N Engl J Med","first-page":"1509","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp SA","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D,  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509\u20131518."},{"key":"B4","series-title":"Am J Hematol","first-page":"666","article-title":"Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"98","author":"Aldoss I","year":"2023","unstructured":"Aldoss I, Shah BD, Park JH,  Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Am J Hematol 2023;98:666\u2013680."},{"key":"B5","series-title":"J Pers Med","first-page":"715","article-title":"Targeted therapy in acute lymphoblastic leukaemia","volume":"11","author":"Salvaris R","year":"2021","unstructured":"Salvaris R, Fedele PL. Targeted therapy in acute lymphoblastic leukaemia. J Pers Med 2021;11:715."},{"key":"B6","series-title":"N Engl J Med","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J,  Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439\u2013448."},{"key":"B7","series-title":"HemaSphere","first-page":"13","article-title":"S112: Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study","volume":"6","author":"Rives S","year":"2022","unstructured":"Rives S, Maude SL, Hiramatsu H,  S112: Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study. HemaSphere 2022;6:13\u201314."},{"key":"B8","series-title":"Blood","first-page":"428","article-title":"Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry","volume":"138","author":"John S","year":"2021","unstructured":"John S, Pulsipher MA, Moskop A,  Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood 2021(Suppl);138:Abstract 428."},{"key":"B9","series-title":"J Clin Oncol","first-page":"945","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz LM","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S,  Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol 2022;40:945\u2013955."},{"key":"B10","series-title":"J Clin Oncol","first-page":"3044","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers RM","year":"2021","unstructured":"Myers RM, Li Y, Leahy AB,  Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2021;39:3044\u20133055."},{"key":"B11","series-title":"Transplant Cell Ther","first-page":"73.e1","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich JW","year":"2022","unstructured":"Ravich JW, Huang S, Zhou Y,  Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel. Transplant Cell Ther 2022;28:73.e1\u201373.e9."},{"key":"B12","series-title":"N Engl J Med","first-page":"449","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park JH","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M,  Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449\u2013459."},{"key":"B13","series-title":"Leukemia","first-page":"3383","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe ME","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K,  Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia 2021;35:3383\u20133393."},{"key":"B14","series-title":"Blood Adv","first-page":"3539","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai V","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W,  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv 2019;3:3539\u20133549."},{"key":"B15","series-title":"Blood Adv","first-page":"1959","article-title":"Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy","volume":"8","author":"Gabelli M","year":"2024","unstructured":"Gabelli M, Oporto-Espuelas M, Burridge S,  Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Adv 2024;8:1959\u20131963."},{"key":"B16","series-title":"Blood Cancer Discov","first-page":"66","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher MA","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL,  Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov 2022;3:66\u201381."},{"key":"B17","series-title":"Transplant Cell Ther","first-page":"S216","article-title":"Predictive value of next-generation sequencing (NGS) following tisagenlecleucel in pediatric and young adult B-cell acute lymphoblastic leukemia","volume":"27","author":"Schultz LM","year":"2021","unstructured":"Schultz LM, Baggott C, Prabhu S,  Predictive value of next-generation sequencing (NGS) following tisagenlecleucel in pediatric and young adult B-cell acute lymphoblastic leukemia. Transplant Cell Ther 2021:27:S216\u2013217."},{"key":"B18","series-title":"Blood","first-page":"2173","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy AB","year":"2022","unstructured":"Leahy AB, Devine KJ, Li Y,  Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood 2022;139:2173\u20132185."},{"key":"B19","series-title":"Blood","first-page":"11","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah BD","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO,  KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 2021;138:11\u201322."},{"key":"B20","series-title":"Lancet","first-page":"491","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah BD","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO,  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491\u2013502."},{"key":"B21","series-title":"J Hematol Oncol","first-page":"170","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah BD","year":"2022","unstructured":"Shah BD, Ghobadi A, Oluwole OO,  Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol 2022;15:170."},{"key":"B22","series-title":"Blood","first-page":"1030","article-title":"Brexucabtagene autoleucel in adults with relapsed\/refractory B-cell ALL: outcomes and novel insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)","volume":"142","author":"Roloff GW","year":"2023","unstructured":"Roloff GW, Aldoss I, Kopmar NE,  Brexucabtagene autoleucel in adults with relapsed\/refractory B-cell ALL: outcomes and novel insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA). Blood 2023;142(Suppl 1):Abstract 1030."},{"key":"B23","series-title":"Blood","first-page":"1029","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry","volume":"142","author":"Bezerra E","year":"2023","unstructured":"Bezerra E, Itani T, Wudhikarn K,  Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry. Blood 2023;142(Suppl 1):Abstract 1029."},{"key":"B24","series-title":"J Clin Oncol","first-page":"7000","article-title":"Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): top line results of the pivotal FELIX study","volume":"41","author":"Roddie C","year":"2023","unstructured":"Roddie C, Sandhu KS, Tholouli E,  Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): top line results of the pivotal FELIX study. J Clin Oncol 2023;41(Suppl):Abstract 7000."},{"key":"B25","series-title":"Blood","first-page":"222","article-title":"Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed\/refractory adult B-cell acute lymphoblastic leukemia (R\/R B-ALL): pooled analysis of the ongoing FELIX phase Ib\/II study","volume":"142","author":"Roddie C","year":"2023","unstructured":"Roddie C, Sandhu KS, Tholouli E,  Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed\/refractory adult B-cell acute lymphoblastic leukemia (R\/R B-ALL): pooled analysis of the ongoing FELIX phase Ib\/II study. Blood 2023;142(Suppl 1):Abstract 222."},{"key":"B26","series-title":"J Clin Invest","first-page":"2123","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle CJ","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C,  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123\u20132138."},{"key":"B27","series-title":"Blood","first-page":"1652","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay KA","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV,  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 2019;133:1652\u20131663."},{"key":"B28","series-title":"J Clin Oncol","first-page":"1650","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah NN","year":"2021","unstructured":"Shah NN, Lee DW, Yates B,  Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39:1650\u20131659."},{"key":"B29","series-title":"Nat Med","first-page":"1408","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian S","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S,  Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 2019;25:1408\u20131414."},{"key":"B30","series-title":"J Clin Oncol","first-page":"415","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey NV","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO,  Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol 2020;38:415\u2013422."},{"key":"B31","series-title":"J Hematol Oncol","first-page":"122","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu R","year":"2020","unstructured":"Gu R, Liu F, Zou D,  Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol 2020;13:122."},{"key":"B32","series-title":"Lancet","first-page":"517","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee DW","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M,  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517\u2013528."},{"key":"B33","series-title":"Blood","first-page":"3322","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner RA","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C,  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017;129:3322\u20133331."},{"key":"B34","series-title":"Blood","first-page":"2361","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran KJ","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA,  Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood 2019;134:2361\u20132368."},{"key":"B35","series-title":"Clin Cancer Res","first-page":"742","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss I","year":"2023","unstructured":"Aldoss I, Khaled SK, Wang X,  Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL. Clin Cancer Res 2023;29:742\u2013753."},{"key":"B36","series-title":"Blood","first-page":"LBA-1","article-title":"Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial","volume":"140","author":"Litzow MR","year":"2022","unstructured":"Litzow MR, Sun Z, Paietta E,  Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial. Blood 2022;140(Suppl 2):Abstract LBA-1."},{"key":"B37","series-title":"Lancet Haematol","first-page":"e878","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N,  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 2022;9:e878\u2013885."},{"key":"B38","series-title":"J Clin Oncol","first-page":"273","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes M","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N,  Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol 2024;42:273\u2013282."},{"key":"B39","series-title":"N Engl J Med","first-page":"1507","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA,  Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507\u20131517."},{"key":"B40","series-title":"Blood","first-page":"2119","article-title":"Impact of prior response to blinatumomab on outcomes of brexucabtagene autoleucel (brexu-cel) in adult patients with relapsed or refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)","volume":"142","author":"Gupta VK","year":"2023","unstructured":"Gupta VK, Roloff GW, Muffly LS,  Impact of prior response to blinatumomab on outcomes of brexucabtagene autoleucel (brexu-cel) in adult patients with relapsed or refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA). Blood 2023;142(Suppl 1):Abstract 2119."},{"key":"B41","series-title":"J Clin Oncol","first-page":"932","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers RM","year":"2022","unstructured":"Myers RM, Taraseviciute A, Steinberg SM,  Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol 2022;40:932\u2013944."},{"key":"B42","series-title":"Blood","first-page":"4877","article-title":"The impact of inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL)","volume":"142","author":"Aldoss I","year":"2023","unstructured":"Aldoss I, Roloff GW, Advani AS,  The impact of inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL). Blood 2023;142(Suppl 1):Abstract 4877."},{"key":"B43","series-title":"J Clin Oncol","first-page":"7001","article-title":"Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed\/refractory B-ALL","volume":"41","author":"Roloff G","year":"2023","unstructured":"Roloff G, Faramand R, Aldoss I,  Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed\/refractory B-ALL. J Clin Oncol 2023;41(Suppl):Abstract 7001."},{"key":"B44","series-title":"J Immunother Cancer","first-page":"e007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah BD","year":"2023","unstructured":"Shah BD, Cassaday RD, Park JH,  Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer 2023;11:e007118."},{"key":"B45","series-title":"Cancer","first-page":"529","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss I","year":"2022","unstructured":"Aldoss I, Otoukesh S, Zhang J,  Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer 2022;128:529\u2013535."},{"key":"B46","series-title":"Haematologica","first-page":"2064","article-title":"Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin","volume":"107","author":"Kayser S","year":"2022","unstructured":"Kayser S, Sartor C, Luskin MR,  Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica 2022;107:2064\u20132071."},{"key":"B47","series-title":"Lancet Haematol","first-page":"e711","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy AB","year":"2021","unstructured":"Leahy AB, Newman H, Li Y,  CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol 2021;8:e711\u2013722."},{"key":"B48","series-title":"Transplant Cell Ther","first-page":"S7","article-title":"Assessment of central nervous system responses in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia receiving brexucabtagene autoleucel as an FDA-approved standard of care","volume":"30","author":"Muhsen IN","year":"2024","unstructured":"Muhsen IN, Roloff G, Kopmar NE,  Assessment of central nervous system responses in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia receiving brexucabtagene autoleucel as an FDA-approved standard of care. Transplant Cell Ther 2024;30(Suppl 2):S7\u20138."},{"key":"B49","series-title":"Front Immunol","first-page":"618427","article-title":"Allogeneic CAR cell therapy-more than a pipe dream","volume":"11","author":"Caldwell KJ","year":"2020","unstructured":"Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR cell therapy-more than a pipe dream. Front Immunol 2020;11:618427."},{"key":"B50","series-title":"Blood","first-page":"3502","article-title":"Bridging therapy in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia receiving standard of care brexucabtagene autoleucel: results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)","volume":"142","author":"Lin C","year":"2023","unstructured":"Lin C, Tsai SB, Roloff GW,  Bridging therapy in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia receiving standard of care brexucabtagene autoleucel: results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA). Blood 2023;142(Suppl 1):Abstract 3502."},{"key":"B51","series-title":"Leukemia","first-page":"3268","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica K","year":"2021","unstructured":"Perica K, Flynn J, Curran KJ,  Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia 2021;35:3268\u20133271."},{"key":"B52","series-title":"Front Immunol","first-page":"1165870","article-title":"Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL","volume":"14","author":"Aparicio-P\u00e9rez C","year":"2023","unstructured":"Aparicio-P\u00e9rez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol 2023;14:1165870."},{"key":"B53","series-title":"Blood","first-page":"2406","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner R","year":"2016","unstructured":"Gardner R, Wu D, Cherian S,  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016;127:2406\u20132410."},{"key":"B54","series-title":"J Clin Oncol","first-page":"1664","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch TW","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S,  Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 2023;41:1664\u20131669."},{"key":"B55","series-title":"Cancer Immunol Immunother","first-page":"689","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang X","year":"2022","unstructured":"Zhang X, Yang J, Li J,  Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immunother 2022;71:689\u2013703."},{"key":"B56","series-title":"Leukemia","first-page":"2587","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan J","year":"2017","unstructured":"Pan J, Yang JF, Deng BP,  High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 2017;31:2587\u20132593."},{"key":"B57","series-title":"Blood","first-page":"4981","article-title":"Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy","volume":"142","author":"Aldoss I","year":"2023","unstructured":"Aldoss I, Shan H, Yang D,  Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy. Blood 2023;142(Suppl 1):Abstract 4981."},{"key":"B58","series-title":"Am J Hematol","first-page":"1113","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang H","year":"2019","unstructured":"Jiang H, Li C, Yin P,  Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol 2019;94:1113\u20131122."},{"key":"B59","series-title":"Blood Adv","first-page":"3062","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman M","year":"2019","unstructured":"Shadman M, Gauthier J, Hay KA,  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv 2019;3:3062\u20133069."},{"key":"B60","series-title":"Blood Adv","first-page":"2182","article-title":"Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers RM","year":"2024","unstructured":"Myers RM, Devine K, Li Y,  Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Adv 2024;8:2182\u20132192."},{"key":"B61","series-title":"Blood","first-page":"323","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier J","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV,  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 2021;137:323\u2013335."},{"key":"B62","series-title":"Cancer","first-page":"2941","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"122","author":"Giebel S","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O,  Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 2016;122:2941\u20132951."},{"key":"B63","series-title":"J Exp Med","first-page":"e20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka A","year":"2020","unstructured":"Tanaka A, Nishikawa H, Noguchi S,  Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 2020;217:e20191009."},{"key":"B64","series-title":"J Hematol Oncol","first-page":"113","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang H","year":"2021","unstructured":"Zhang H, Hu Y, Shao M,  Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. J Hematol Oncol 2021;14:113\u2013116."},{"key":"B65","series-title":"Eur J Haematol","first-page":"137","article-title":"Case report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation","volume":"112","author":"Canale FA","year":"2024","unstructured":"Canale FA, Pitea M, Alati C,  Case report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. Eur J Haematol 2024;112:137\u2013140."},{"key":"B66","series-title":"Blood Adv","first-page":"4913","article-title":"Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia","volume":"7","author":"Chen LY","year":"2023","unstructured":"Chen LY, Gong WJ, Li MH,  Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv 2023;7:4913\u20134925."},{"key":"B67","series-title":"Br J Haematol","first-page":"711","article-title":"Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"205","author":"Othman T","year":"2024","unstructured":"Othman T, Koller P, Pourhassan H,  Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2024;205:711\u2013715."},{"key":"B68","series-title":"Sci Transl Med","first-page":"eaau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann K","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J,  The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med 2019;11:eaau5907."},{"key":"B69","series-title":"Nat Med","first-page":"1710","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park JH","year":"2023","unstructured":"Park JH, Nath K, Devlin SM,  CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med 2023;29:1710\u20131717."},{"key":"B70","series-title":"Nat Med","first-page":"20","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry TJ","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ,  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24:20\u201328."},{"key":"B71","series-title":"J Clin Oncol","first-page":"1938","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah NN","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H,  CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol 2020;38:1938\u20131950."},{"key":"B72","series-title":"Sci Transl Med","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin H","year":"2019","unstructured":"Qin H, Dong Z, Wang X,  CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med 2019;11."},{"key":"B73","series-title":"Nat Commun","first-page":"217","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong DP","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K,  A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 2022;13:217."},{"key":"B74","series-title":"Blood","first-page":"629","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin H","year":"2015","unstructured":"Qin H, Cho M, Haso W,  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015;126:629\u2013639."},{"key":"B75","series-title":"Blood","first-page":"17","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang N","year":"2020","unstructured":"Wang N, Hu X, Cao W,  Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 2020;135:17\u201327."},{"key":"B76","series-title":"Leukemia","first-page":"963","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz LM","year":"2024","unstructured":"Schultz LM, Jeyakumar N, Kramer AM,  CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 2024;38:963\u2013968."},{"key":"B77","series-title":"Am J Hematol","first-page":"671","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu S","year":"2021","unstructured":"Liu S, Deng B, Yin Z,  Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 2021;96:671\u2013679."},{"key":"B78","series-title":"Blood","first-page":"469","article-title":"CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory ALL","volume":"138","author":"Frey NV","year":"2021","unstructured":"Frey NV, Gill S, Hwang WT,  CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory ALL. Blood 2021;138(Suppl 1):Abstract 469."},{"key":"B79","series-title":"Blood","first-page":"470","article-title":"SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley C","year":"2021","unstructured":"Annesley C, Summers C, Pulsipher MA,  SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL. Blood 2021;138(Suppl 1):Abstract 470."},{"key":"B80","series-title":"Blood","first-page":"1753","article-title":"Tandem CD19\/CD22 dual targets CAR T-cells bridging hematopoietic stem cells transplantation acquires robust remission for relapsed and refractory B acute lymphoblastic leukemia patients","volume":"138","author":"Cui W","year":"2021","unstructured":"Cui W, Zhang X, Dai H,  Tandem CD19\/CD22 dual targets CAR T-cells bridging hematopoietic stem cells transplantation acquires robust remission for relapsed and refractory B acute lymphoblastic leukemia patients. Blood 2021;138(Suppl 1):Abstract 1753."},{"key":"B81","series-title":"J Hematol Oncol","first-page":"53","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai H","year":"2020","unstructured":"Dai H, Wu Z, Jia H,  Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13:53."},{"key":"B82","series-title":"Blood","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel JY","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD,  Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 2021;137:1832\u20131835."},{"key":"B83","series-title":"Nat Med","first-page":"1797","article-title":"CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba S","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S,  CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021;27:1797\u20131805."},{"key":"B84","series-title":"Lancet","first-page":"1885","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin R","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D,  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 2020;396:1885\u20131894."},{"key":"B85","series-title":"Lancet Haematol","first-page":"e833","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin R","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV,  UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol 2022;9:e833\u2013843."},{"key":"B86","series-title":"Blood","first-page":"650","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic \u2018off-the-shelf\u2019CD19-directed CAR-T for patients with relapsed\/refractory (R\/R) CD19+ B-ALL","volume":"138","author":"Jain N","year":"2021","unstructured":"Jain N, Kantarjian H, Solomon SR,  Preliminary safety and efficacy of PBCAR0191, an allogeneic \u2018off-the-shelf\u2019CD19-directed CAR-T for patients with relapsed\/refractory (R\/R) CD19+ B-ALL. Blood 2021;138(Suppl 1):Abstract 650."},{"key":"B87","series-title":"Blood","first-page":"1746","article-title":"Preliminary results from the flu\/cy\/alemtuzumab arm of the phase I BALLI-01 trial of UCART22, an anti-CD22 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL)","volume":"138","author":"Jain N","year":"2021","unstructured":"Jain N, Roboz GJ, Konopleva M,  Preliminary results from the flu\/cy\/alemtuzumab arm of the phase I BALLI-01 trial of UCART22, an anti-CD22 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL). Blood 2021;138(Suppl 1):Abstract 1746."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-e247065.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-e247065.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-e247065.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:47:04Z","timestamp":1729082824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-e247065.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":87,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7065","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}